caa a22 4500 606184287 CHVBK 20210128100825.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s00405-015-3604-y doi (NATIONALLICENCE)springer-10.1007/s00405-015-3604-y Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2 [Elektronische Daten] [Said Farschtschi, Philipp Kollmann, Carsten Dalchow, Alexander Stein, Victor-Felix Mautner] Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular schwannomas and other benign tumors of the central nervous system. Bevacizumab is used for treatment of progressive vestibular schwannomas, with the intent to reduce tumor size or preserve/improve hearing. Prolonged treatment can cause side effects such as hypertension and proteinuria, which can be cause for discontinuation of therapy. We report on 3 patients who were treated with bevacizumab for 66-76months, with dose reductions that minimized side effects while sustaining the clinical effect of the antiangiogenic therapy. After dose reduction from 5mg/kg bi- or tri-weekly to 2.5mg bi- or tri-weekly, all patients appeared clinically stable and radiographic and audiologic follow-up showed sustained response. In conclusion, in some NF2 patients, dose reduction of bevacizumab seems to be an effective option for managing side effects. Springer-Verlag Berlin Heidelberg, 2015 Neurofibromatosis nationallicence Vestibular schwannoma nationallicence Bevacizumab nationallicence NF2 nationallicence VEGF nationallicence Dose reduction nationallicence Farschtschi Said Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut Kollmann Philipp Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut Dalchow Carsten Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut Stein Alexander Department of Internal Medicine II and Clinic (Oncology Center), University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut Mautner Victor-Felix Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/12(2015-12-01), 3857-3860 0937-4477 272:12<3857 2015 272 405 https://doi.org/10.1007/s00405-015-3604-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00405-015-3604-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Farschtschi Said Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut NATIONALLICENCE 700 1- Kollmann Philipp Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut NATIONALLICENCE 700 1- Dalchow Carsten Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut NATIONALLICENCE 700 1- Stein Alexander Department of Internal Medicine II and Clinic (Oncology Center), University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut NATIONALLICENCE 700 1- Mautner Victor-Felix Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany aut NATIONALLICENCE 773 0- European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/12(2015-12-01), 3857-3860 0937-4477 272:12<3857 2015 272 405